Copyright
©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 80-93
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Inhibitor | Tyrosine kinase target | Neoplasm(s) targeted | Clinical status |
Leflunomide (SU101) | PDGFRβ, EGFR, FGFR | Prostate cancer | Phase II/III |
Lestaurtinib (CEP-701) | Flt3, Trk, VEGFR2 | Leukemia, pancreatic, AML | Phase II |
Tandutinib (MLN518) | Flt3, PDGFRβ, Kit | AML | Phase I/II |
SU14813 | VEGFR2, PDGFRβ, Flt3 | Adv malignancies | Phase I, suspended |
XL999 | FGFR, VEGFR1/2/3, PDGFRβ, Flt3 | Cancer | Phase II, suspended |
VX-322 | Flt3, Kit | AML | Preclinical |
SU5614 | Flt3 | AML, solid tumors | Preclinical, suspended |
GTP-14564 | Flt3 | AML | Preclinical |
KI23819 | Flt3 | AML | Preclinical |
Gö6976 | Flt3, JAK2 | AML | Preclinical |
AG1296 | PDGFRβ, Kit, Flt3 | AML | Preclinical |
PKC412 | Kit, PDGFRβ, PKC, Flt3, VEGFR2 | Solid tumors | Phase II |
OSI 817 | Kit, VEGFR | Solid tumors | Preclinical |
CP-868596 | PDGFRβ | Adv solid tumors | Phase I |
NSCLC | Phase II |
- Citation: Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011; 2(2): 80-93
- URL: https://www.wjgnet.com/2218-4333/full/v2/i2/80.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i2.80